Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension
NCT ID: NCT00709930
Last Updated: 2009-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2007-12-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1,Exposed to ELF-EMF
Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
Magnetic field generator
dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
2,Placebo
Device: Placebo device with no magnetic fields
Placebo magnetic field generator
Placebo device with no magnetic fields
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnetic field generator
dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
Placebo magnetic field generator
Placebo device with no magnetic fields
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Genders : Both
* The severity of hypertension: mild and moderate (WHO/ISH criteria stage I-II) Systolic blood pressure (SBP) \>/= 140 and/or diastolic blood pressure (DBP)\>/= 90 (untreated hypertension cases)
Exclusion Criteria
* Severe essential hypertension (DBP \>110)
* Secondary or malignant hypertension
* History or symptoms of cerebral vascular disease
* History of myocardial infarction
* History of angina pectoris, atrial fibrillation, heart failure and arrhythmia
* Renal dysfunction (serum creatinine \> 2.1mg/dl)
* Severe hepatic dysfunction
* Uncontrolled diabetes
* Allergy, drug sensitivity or chronic skin disease
* Peptic ulcer disease
* Current pregnancy or lactation
* Depression that needs to be treated
* Hypertension controlled with antihypertensive medication
20 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyoto University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Translarional Research center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masanori Fukushima
Role: PRINCIPAL_INVESTIGATOR
Kyoto University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyoto University Hospital
Kyoto, Kyoto, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MF-II-01
Identifier Type: -
Identifier Source: org_study_id